ValuEngine lowered shares of Nivalis Therapeutics, Inc. (NASDAQ:ALPN) from a hold rating to a sell rating in a report issued on Wednesday, August 2nd.
Several other analysts have also commented on ALPN. Ladenburg Thalmann Financial Services initiated coverage on shares of Nivalis Therapeutics in a research report on Thursday, July 27th. They issued a buy rating and a $17.00 price objective on the stock. Zacks Investment Research raised shares of Nivalis Therapeutics from a hold rating to a buy rating and set a $3.00 price objective on the stock in a research report on Wednesday, April 19th. Finally, Cowen and Company reaffirmed a hold rating on shares of Nivalis Therapeutics in a research report on Wednesday, April 19th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company’s stock. Nivalis Therapeutics currently has an average rating of Hold and an average target price of $8.81.
Shares of Nivalis Therapeutics (ALPN) traded down 0.45% during midday trading on Wednesday, reaching $8.77. 13,016 shares of the company’s stock traded hands. Nivalis Therapeutics has a 12 month low of $8.00 and a 12 month high of $37.40. The stock has a 50 day moving average of $9.30 and a 200-day moving average of $9.82. The stock’s market cap is $11.75 million.
COPYRIGHT VIOLATION WARNING: “Nivalis Therapeutics, Inc. (ALPN) Downgraded by ValuEngine” was first posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.baseball-news-blog.com/2017/08/13/nivalis-therapeutics-inc-alpn-rating-lowered-to-sell-at-valuengine-updated.html.
In other Nivalis Therapeutics news, insider Value Fund L. P. Biotechnology purchased 47,000 shares of the stock in a transaction dated Wednesday, May 31st. The shares were bought at an average price of $2.27 per share, with a total value of $106,690.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bvf Partners L. P/Il purchased 35,750 shares of the stock in a transaction dated Monday, June 5th. The stock was acquired at an average cost of $2.29 per share, for a total transaction of $81,867.50. The disclosure for this purchase can be found here. In the last three months, insiders bought 288,964 shares of company stock worth $660,495. Insiders own 3.00% of the company’s stock.
About Nivalis Therapeutics
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.